From: Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
ACCLAIM/COPD I | ACCLAIM/COPD II | |||
---|---|---|---|---|
Aclidinium 200 μg (n = 627) n (%) | Placebo (n = 216) n (%) | Aclidinium 200 μg (n = 600) n (%) | Placebo (n = 204) n (%) | |
Total AEs | 355 (56.6) | 128 (59.3) | 479 (79.8) | 154 (75.5) |
SAEs | 50 (8.0) | 22 (10.2) | 62 (10.3) | 23 (11.3) |
Deaths | 7 (1.1) | 4 (1.9) | 6 (1.0) | 3 (1.5) |
Cardiac disorders* | 32 (5.1) | 14 (6.5) | 41 (6.8) | 17 (8.3) |
Vascular disorders* | 22 (3.5) | 14 (6.5) | 34 (5.7) | 12 (5.9) |